Testing PTX-912 in patients with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and tolerability of PTX-912, an investigational drug, in patients with locally advanced or metastatic solid tumors. Participants will receive PTX-912 through intravenous infusion every two weeks, with the treatment continuing until disease progression, unacceptable toxicity, or a maximum of 12 months. The study aims to assess the pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of PTX-912. It is a first-in-human Phase I study, focusing on escalating doses to determine the optimal therapeutic approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.
2. Male and Female patients age ≥ 18 years on day of signing informed consent.
3. Willing to comply with all protocol-required visits, assessments, and procedures.
4. Patients with locally advanced or metastatic solid tumors who have had disease progression on all available standard of care or for whom no reasonable standard of care exists that would confer clinical benefit.
5. Recovery from all toxicities associated with prior therapy to acceptable baseline status (for laboratory toxicities, see limits for inclusion). NCI CTCAE v5.0 Grade 0 or 1, except for toxicities not considered a safety risk (e.g., alopecia or vitiligo).
6. Measurable disease per RECIST v1.1.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no deterioration during Screening.
8. Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug.
9. Patients with recent major surgery must have adequately recovered with no ongoing complications from the surgery prior to receiving study treatment.
10. Willingness to adhere to the study treatment-specific contraception requirements.
11. Estimated life expectancy of 3 months (12 weeks) or greater as determined by Investigator.

Exclusion Criteria:

1. Has a diagnosis of immunodeficiency.
2. Has an active infection requiring systemic therapy within 4 weeks prior to study treatment.
3. History of or known intolerance, significant hypersensitivity, or anaphylaxis to any components of PTX-912 or any of the excipients.
4. Unresolved toxicities from prior systemic therapy greater than NCI CTCAE grade 1 at time of first dose, except alopecia, vitiligo, and grade 2 neuropathy due to prior chemotherapy.
5. Experienced clinically significant immune-related toxicity from prior immunotherapy that in the opinion of the investigator would preclude protocol therapy or would make the patient inappropriate for the study.
6. Major surgery within 30 days prior to first dose of study drug (with the below exceptions), or anticipation of major surgery during study treatment.
7. Active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents.
8. Uncontrolled diabetes mellitus or other uncontrolled immune-related endocrinopathies in the opinion of the investigator.
9. Primary central nervous system (CNS) disease or leptomeningeal disease.
10. Impaired cardiovascular function or clinically significant cardiovascular disease.
11. Abnormal pulmonary function within the previous 6 months, including history of pneumonitis, active pneumonitis, interstitial lung disease requiring the use of steroids, idiopathic pulmonary fibrosis, active pleural effusion, severe dyspnea at rest or requiring supplementary oxygen therapy.
12. History of allogenic, bone marrow, or solid organ transplants.
13. Received a live-virus vaccination ≤14 days prior to first dose of study drug (seasonal flu and other inactivated vaccines that do not contain live virus are permitted).
14. Clinically significant bleeding within 2 weeks prior to first dose of study drug dy.
15. Pregnant or breast-feeding women or expecting to conceive within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of study drug.

Where it's running

• City of Hope National Medical Center
  Duarte, California, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Nebraska Cancer Specialists (NCS)
  Omaha, Nebraska, United States Recruiting

Study contacts

• Study coordinator: Project Manager
• Email: ze.zhang@provivatx.com
• Phone: 425-233-1480

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

• Evaluating INX-315 for advanced cancer treatment

  This study is testing a new oral medication called INX-315 to see if it can safely help people with advanced cancers, including breast and ovarian cancer, who haven't responded to other treatments.

  Recruiting at 17 sites Phase 1/2 Incyclix Bio · Orlando, Florida and 17 other locations · NCT05735080

• Oncolytic virus treatment combined with nivolumab for advanced solid tumors

  This study is testing a new virus treatment combined with an existing cancer drug to see if it can help people with advanced solid tumors, like lung cancer, whose cancer has not improved with previous treatments.

  Recruiting Phase 1 Memgen, Inc. · Tampa, Florida and 1 other locations · NCT05076760

• Evaluating TJ033721 for advanced or metastatic solid tumors

  This study is testing a new drug called TJ033721 to see if it can help people with advanced or metastatic solid tumors, both on its own and in combination with other treatments.

  Recruiting at 7 sites Phase 1 I-Mab Biopharma US Limited · Orange, California and 20 other locations · NCT04900818

• BMS-986504 with olaparib for advanced solid tumors that have MTAP loss

  This study tests whether combining BMS-986504 with olaparib is safe and has anti-tumor activity in adults with advanced solid tumors that have MTAP loss.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07382544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.